{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T02:13:20Z","timestamp":1781662400464,"version":"3.54.5"},"reference-count":32,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2017,11,11]],"date-time":"2017-11-11T00:00:00Z","timestamp":1510358400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"name":"Minist\u00c3\u0308re de la Sant\u00c3\u00a9 et des Services Sociaux (MSSS) du Qu\u00c3\u00a9bec"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Journal of Medical Virology"],"published-print":{"date-parts":[[2018,3]]},"abstract":"<jats:sec><jats:label\/><jats:p>In Qu\u00e9bec province in Canada, a public school\u2010based and catch\u2010up HPV vaccination programs with the quadrivalent vaccine have been introduced in September 2008 for girls aged 9\u201017 years. We assessed the early impact of the HPV vaccination program on the incidence of anogenital warts (AGW) in the Quebec general population. We used the provincial health administrative data of the <jats:italic>R\u00e9gie de l'assurance maladie du Qu\u00e9bec<\/jats:italic> (RAMQ). AGW were identified either through a prescription of podofilox, or a medical procedure code specific to AGW, or a diagnostic code for viral warts followed by a prescription of imiquimod or fluorouracil. Sex\u2010 and age\u2010specific incidence rates were calculated for pre\u2010vaccination (2004\u20102007) and vaccination (2009\u20102012) periods. We found a significant decline of 45% and 19% in the incidence of AGWs among females aged 15\u201019 and 20\u201024 years, respectively. A decline of 21% was also seen among males aged 15\u201019 years. The median age at an episode of AGW increased from 27 years in 2004 to 31 years in 2012 among females and remained stable in males. Our findings indicate that the HPV public vaccination program is associated with an important reduction in the incidence of AGW among young females and males. The benefit is more pronounced among females 15\u201019 years of age, who were eligible for the public vaccination program. The observed decline among young males could be due to herd immunity and\/or privately paid vaccination.<\/jats:p><\/jats:sec>","DOI":"10.1002\/jmv.24968","type":"journal-article","created":{"date-parts":[[2017,10,5]],"date-time":"2017-10-05T14:00:42Z","timestamp":1507212042000},"page":"592-598","source":"Crossref","is-referenced-by-count":14,"title":["The early impact of human papillomavirus vaccination on anogenital warts in Qu\u00e9bec, Canada"],"prefix":"10.1002","volume":"90","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1136-3208","authenticated-orcid":false,"given":"Marc","family":"Steben","sequence":"first","affiliation":[{"name":"Sexually Transmitted Infections unit Institut national de sant\u00e9 publique du Qu\u00e9bec Montr\u00e9al Qu\u00e9bec Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Najwa","family":"Ouhoummane","sequence":"additional","affiliation":[{"name":"Sexually Transmitted Infections unit Institut national de sant\u00e9 publique du Qu\u00e9bec Montr\u00e9al Qu\u00e9bec Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline","family":"Rodier","sequence":"additional","affiliation":[{"name":"Merck Canada Inc. Kirkland Qu\u00e9bec Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liliya","family":"Sinyavskaya","sequence":"additional","affiliation":[{"name":"Center for Outcome Research and Evaluation McGill University Health Center Montr\u00e9al Qu\u00e9bec Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7485-2546","authenticated-orcid":false,"given":"Paul","family":"Brassard","sequence":"additional","affiliation":[{"name":"Center for Outcome Research and Evaluation McGill University Health Center Montr\u00e9al Qu\u00e9bec Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2017,11,11]]},"reference":[{"key":"e_1_2_9_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(07)70158-5"},{"key":"e_1_2_9_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2214-109X(16)30099-7"},{"key":"e_1_2_9_4_1","unstructured":"Report of the meeting on HPV Vaccine coverage and impact monitoring 16\u201317 November 2009 Geneva Switzerland. 2010 World Health Organization (WHO)."},{"key":"e_1_2_9_5_1","unstructured":"Goggin P Coutl\u00e9eF DefayF et al. Prevalence of genital HPV infection in women aged 17\u201329 in the post\u2010vaccinated period Qu\u00e9bec Canada in European Research Organization on Genital Infection and Neoplasia (EUROGIN). 2015: Seville Spain."},{"key":"e_1_2_9_6_1","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.2014.198"},{"key":"e_1_2_9_7_1","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jit192"},{"key":"e_1_2_9_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2013.10.085"},{"key":"e_1_2_9_9_1","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jis590"},{"key":"e_1_2_9_10_1","doi-asserted-by":"publisher","DOI":"10.1086\/597071"},{"key":"e_1_2_9_11_1","doi-asserted-by":"crossref","first-page":"2058","DOI":"10.1128\/jcm.33.8.2058-2063.1995","article-title":"Human papillomavirus (HPV) type distribution and serological response to HPV type 6 virus\u2010like particles in patients with genital warts","volume":"33","author":"Greer CE","year":"1995","journal-title":"J Clin Microbiol"},{"key":"e_1_2_9_12_1","doi-asserted-by":"publisher","DOI":"10.1097\/OLQ.0b013e3182215512"},{"key":"e_1_2_9_13_1","doi-asserted-by":"publisher","DOI":"10.1136\/sti.2009.037028"},{"key":"e_1_2_9_14_1","doi-asserted-by":"publisher","DOI":"10.1097\/LGT.0b013e3182466ee3"},{"key":"e_1_2_9_15_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.f2032"},{"key":"e_1_2_9_16_1","doi-asserted-by":"publisher","DOI":"10.1097\/OLQ.0b013e31827bd66b"},{"key":"e_1_2_9_17_1","doi-asserted-by":"publisher","DOI":"10.2105\/AJPH.2011.300465"},{"key":"e_1_2_9_18_1","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jis405"},{"key":"e_1_2_9_19_1","doi-asserted-by":"publisher","DOI":"10.1097\/OLQ.0b013e3182756efd"},{"key":"e_1_2_9_20_1","first-page":"51","article-title":"Impact of the human papillomavirus (HPV) vaccine on genital wart diagnoses at Auckland Sexual Health Services","volume":"124","author":"Oliphant J","year":"2011","journal-title":"N Z Med J"},{"key":"e_1_2_9_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(14)71073-4"},{"key":"e_1_2_9_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2016.08.020"},{"key":"e_1_2_9_23_1","unstructured":"KlieverE DemersAA. Quadrivalent HPV vaccination and the incidence of anogenital warts in Manitoba Canada in 28th International Papillomavirus Conference and Clinical and Public Health worshops. 2012: Puerto Rico."},{"key":"e_1_2_9_24_1","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2014-2961"},{"key":"e_1_2_9_25_1","unstructured":"SauvageauC GilcaV.La vaccination des pr\u00e9\u2010adolescents contre les virus du papillome humain (VPH) au Qu\u00e9bec: deux ou trois doses? Comit\u00e9 de l'immunisation du Qu\u00e9bec Institut national de sant\u00e9 publique du Canada 2013: p. 73 pages."},{"key":"e_1_2_9_26_1","unstructured":"MSSS Flash Vigie [Internet]. Available from:http:\/\/publications.msss.gouv.qc.ca\/msss\/fichiers\/flashvigie\/06\u2010271\u201002W\u2010vol8_no7.pdf 2013"},{"key":"e_1_2_9_27_1","unstructured":"GuayM Cl\u00e9mentP HamidA et al. Institut national de sant\u00e9 publique du Qu\u00e9bec. \u00c9valuation de l'implantation du Programme de vaccination contre les virus du papillome humain (VPH) chez les adolescentes du Qu\u00e9bec [Internet]. Montr\u00e9al Qu\u00e9bec. Available from:https:\/\/www.inspq.qc.ca\/pdf\/publications\/1561_EvalImplanProgVaccVPHAdoQc.pdf 2013"},{"key":"e_1_2_9_28_1","doi-asserted-by":"publisher","DOI":"10.1097\/LGT.0b013e31825c3915"},{"key":"e_1_2_9_29_1","doi-asserted-by":"publisher","DOI":"10.1097\/OLQ.0b013e318198de8c"},{"key":"e_1_2_9_30_1","doi-asserted-by":"publisher","DOI":"10.1136\/sti.2008.030999"},{"key":"e_1_2_9_31_1","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jir285"},{"key":"e_1_2_9_32_1","doi-asserted-by":"publisher","DOI":"10.1136\/sextrans-2011-050234"},{"key":"e_1_2_9_33_1","doi-asserted-by":"publisher","DOI":"10.1097\/OLQ.0000000000000369"}],"container-title":["Journal of Medical Virology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fjmv.24968","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/jmv.24968","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,29]],"date-time":"2023-09-29T02:30:09Z","timestamp":1695954609000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/jmv.24968"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,11,11]]},"references-count":32,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2018,3]]}},"alternative-id":["10.1002\/jmv.24968"],"URL":"https:\/\/doi.org\/10.1002\/jmv.24968","archive":["Portico"],"relation":{},"ISSN":["0146-6615","1096-9071"],"issn-type":[{"value":"0146-6615","type":"print"},{"value":"1096-9071","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,11,11]]}}}